Report on the financial statements of S & B Holdings B.V., Netherlands, a foreign subsidiary of Alkem Laboratories Limited, India required for the purposes of Section 129(3) of the Companies Act, 2013 and its consolidation with the financial statements of the holding company.

Independent Auditor's Report

To,
The Board of Directors,
Alkem Laboratories Limited, India

Report on the Standalone Ind AS Financial Statements:

We have audited the accompanying standalone Ind AS financial statements of **S & B Holdings B.V., Netherlands** ('the Company') which comprise the Balance Sheet as at 31st March, 2017, the statement of Profit & Loss (including Other Comprehensive Income), the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "standalone Ind AS financial statements") prepared by its management in its reporting currency in Euro. These financial statements are translated by the management of its holding company M/s Alkem Laboratories Ltd., India in Indian currency (INR) and is also presented in the formats and as per requirements of Division II of Schedule III to the Companies Act, 2013 and as per Ind AS, for the purpose of presenting to its shareholders as required by Section 129(3) of the Companies Act, 2013 and for the purpose of its consolidation with the financial statements of the holding company Alkem Laboratories Limited, India.

Management's Responsibility for the Standalone Financial Statements:

The Company's Board of Directors is responsible for preparation of these Ind AS standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India including the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the act read with relevant rules issued thereunder.

This responsibility also includes maintenance of adequate accounting records for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility:

Our responsibility is to express an opinion on these standalone Ind AS financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder to the extent applicable.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical

requirements and plan and perform the audit to obtain reasonable assurance about whether the standalone Ind AS financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the standalone Ind AS financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the standalone Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.

Opinion:

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone Ind AS financial statements give the information required in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including the Ind AS, of the financial position of the Company as at 31st March, 2017, and its financial performance including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Report on Other Legal and regulatory Requirements:

- 1. This audit is for the purpose of presenting the standalone Ind AS financial statements in Indian currency (INR) and in the formats and as per requirements of Division II of Schedule III to the Companies Act, 2013 as per Ind AS, for the purpose of presenting it to the shareholders of the holding company as required by Section 129(3) of the Companies Act, 2013 and for the purpose of its consolidation with the financial statements of the holding company Alkem Laboratories Limited, India and is not a report under Section 143 of the Companies Act, 2013, and accordingly does not include any statement on the matters specified in and required by Section 143 (11), 143(3)(g) and 143(3)(i) of the Companies Act, 2013 and Rule 11 of the Companies (Audit and Auditors') Rules, 2014 including the Companies (Auditors' Report) Order, 2016;
- 2. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- 3. In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- 4. The Balance Sheet, the Statement of Profit and Loss, the Cash Flows Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
- 5. In our opinion, the aforesaid standalone Ind AS financial statements comply with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013.

CHATERED ACCOUNTANTS FRA 103004 W

6. In our opinion, the standalone Ind AS financial statements dealt with by this report are translated from Euro to Indian Rupees by adopting the applicable rates of foreign currency for the year in accordance with Ind AS-21 prescribed by the Companies (Indian Accounting Standard) Rules, 2015.

For R.S.SANGHAI & ASSOCIATES

Chartered Accountants

Firm Registration No. 109094W

R.S.SANGHAI

Partner

Membership No.: 036931 Mumbai: 22nd May, 2017

S & B HOLDINGS B.V. SEPARATE FINANCIAL STATEMENTS BALANCE SHEET AS ON 31ST MARCH, 2017

	Note	As at	As at	As at	As at	As at	As a
Particulars	No.	31st March, 2017	31st March, 2017	31st March, 2016	31st March, 2016	1st April, 2015	1st April, 2015
	140.	EURO	Rs.	EURO	Rs.	EURO	Rs.
I. ASSETS							
1 Non-current assets							
(a) Financial Assets							
(i) Investments	3.1	299,09,841	20534,64,903	299,09,841	20534,64,904	299,09,841	20534,64,904
(ii) Loans	3.2			30,06,582	2249,60,549	31,49,337	2136,68,992
(b) Other non-current assets	3.3	8,04,433	559,16,299			7-2	-
(c) Deferred tax assets (Net)	1 4	108,94,926	7573,08,474	109,39,630	8185,32,666	115,56,579	7840,64,186
Total Non- current assets		416,09,200	28666,89,676	438,56,053	30969,58,119	446,15,757	30511,98,082
2 Current assets							
(a) Financial Assets							
(i) Investments	3.4	16,367	11,37,646	11,256	8,42,233	11,256	8,91,486
(ii) Cash and Cash Equivalents	3.5	1,60,744	111,73,354	13,63,378	1020,11,618	11,35,091	770,11,037
(iii) Accrued interest and other receivables	3.6	5.	*	6,32,223	473,04,650	4,87,026	330,42,609
(b) Other current assets	3.7	15,401	10,70,526	39	2,907	39	2,637
Total Current assets		1,92,512	133,81,526	20,06,896	1501,61,408	16,33,412	1109,47,769
TOTAL ASSETS		418,01,711	28800,71,202	458,62,949	32471,19,527	462,49,169	31621,45,851
II. EQUITY AND LIABILITIES							
1 Equity	1 1						
(a) Equity Share Capital	3.8	355,90,552	28972,17,375	355,90,552	28972,17,375	355,90,552	28972,17,375
(b) Other Equity	"	(36,92,824)	(7055,73,998)	24,77,160	(2333,58,472)	91,40,439	1619,26,698
Total Equity		318,97,728	21916,43,377	380,67,712	26638,58,903	447,30,991	30591,44,073
2 Current liabilities							
(a) Financial Liabilities						1	
(i) Other financial liabilities	3.9	86,39,828	6005,56,184	63,44,194	4746,89,744	3.09.213	209.78.755
(b) Current Tax Liabilities (Net)	3.10	12,64,155	878,71,641	14,51,042	1085.70.880	12.08.965	820,23,023
Total Current Liabilities	"	99,03,983	6884,27,825	77,95,237	5832,60,624	15,18,178	1030,01,778
TOTAL EQUITY AND LIABILITIES		418,01,711	28800.71,202	458.62.949	32471.19.527	462,49,169	31621,45,851

Significant Accounting Policies Notes to Accounts

ACCOUNTAN

The accompanying notes are an integral part of financial statements.

As per our attached report of even date for R.S.SANGHAI & ASSOCIATES

Chartered Accountants

R.S.SANGHAI

Partner Place : Mumbai

Dated: 22nd May, 2017

For and on behalf of the Board

Manish Narang

S & B HOLDINGS B.V. SEPARATE FINANCIAL STATEMENTS STATEMENT OF PROFIT AND LOSS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

GHAI & AS

CHARTERED ACCOUNTANTS FRN-109094 W

MUMBA

Particulars	Note No.	For the Year ended 31st March, 2017	For the Year ended 31st March, 2017	For the Year ended 31st March, 2016	For the Year ended 31st March, 2016
		EURO	Rs.	EURO	Rs.
1 Income					
(a) Revenue from Operations		9			50
(b) Other Income	3.11	1,71,360	125,94,191	2,20,258	997,24,332
Total Income		1,71,360	125,94,191	2,20,258	997,24,332
2 Expenses					
(a) Finance Costs	3.12	2,097	1,54,112	2,281	1,64,025
(b) Other expenses	3.13	1,59,554	304,75,129	78,442	56,40,932
Total Expenses		1,61,651	306,29,241	80,723	58,04,957
3 Profit before tax (1) - (2)		9,709	(180,35,050)	1,39,535	939,19,375
4 Tax expenses					
(a) Current tax		61,34,988	4508,94,854	61,85,866	4448,38,511
(b) Deferred tax		44,705	32,85,622	6,16,948	443,66,033
	-	61,79,693	4541,80,477	68,02,814	4892,04,545
5 Profit for the period (3) - (4)		(61,69,984)	(4722,15,526)	(66,63,279)	(3952,85,170)
6 Other Comprehensive Income					
Total of Other Comprehensive Income for the period, net of tax			12		_ ==
7 Total Comprehensive Income for the period (5) + (6)		(61,69,984)	(4722,15,526)	(66,63,279)	(3952,85,170)
8 Basic and diluted earnings per share		(0.17)	(13.27)	(0.19)	(11.11)

As per our attached report of even date For R.S.SANGHAI & ASSOCIATES

Chartered Accountants

R.S.SANGHAI Partner

Place : Mumbai Dated: 22nd May, 2017 For and on behalf of the Board

10.NO Manish Narang

S & B HOLDINGS B.V. SEPARATE FINANCIAL STATEMENT CASH FLOW STATEMENT FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

Particulars	Year ending 31st	March, 2017	Year ending 31st March, 2016		
-	Euro	Rs.	Euro	Rs.	
A. Cash Flow from Operating activities					
Profit before Tax	9,709	(180,35,050)	1,39,535	939,19,375	
Adjustments for :	3,.33	(100,00,000,	,,00,,000	,,	
Interest Expense	2,097	1,54,112	2,281	1,64,025	
Operating Profit before Working Capital Changes	11,806	(178,80,938)	1,41,816	940,83,400	
Adjustments for :					
Other current assets	6,16,861	453,36,600	(1,45,197)	(104,41,448	
Other financial liability	22,95,634	1687,19,070	60,34,981	4339,88,079	
Cash (used in) / Generated from Operations before tax	29,24,301	1961,74,732	60,31,600	5176,30,031	
Less: Tax Paid	(63,21,877)	(4646,30,349)	(59,43,788)	(4274,30,160	
Net cash (used in) /generated from operating activities	(33,97,576)	(2684,55,617)	87,812	901,99,871	
B. Cash Flow from Investing activities					
Investment in Equity Instruments-Associates	(5,110)	(3,75,578)			
Loans and Advances to Subsidiary Companies	30,06,582	2209,70,661	1,42,755	102,65,829	
Net cash (used in) /generated from Investing activities	30,01,472	2205,95,083	1,42,755	102,65,829	
C. Cash Flow from Financing activities					
Interest Expense	(2,097)	(1,54,112)	(2,281)	(1,64,025	
Net cash (used In) /generated from Financing activities	(2,097)	(1,54,112)	(2,281)	(1,64,025	
Net Increase/(decrease) in cash and cash equivalents (A + B + C)	(3,98,201)	(480,14,647)	2,28,286	1003,01,675	
Cash and Cash Equivalents at the beginning of the year	13,63,378	1020,11,618	11,35,091	770,11,037	
Cash and Cash Equivalents at the end of the year	9,65,177	539,96,971	13,63,377	1773,12,712	
Notes :					
1) Cash and Cash Equivalents include					
	A4 24 -4 84 -	L 0047	A = =4 O4 =4 B4	L 0040	

Particulars	As at 31st M	arch, 2017	As at 31st March, 2016	
T di di di di di	Euro	Rs.	Euro	Rs.
Cash and Bank balances (Refer Note 3.5)	1,60,744	111,73,354	13,63,378	1020,11,618
Exchange difference (Unrealised (Gain) / Loss)		428,23,617	¥.	753,01,094
Total	1,60,744	539,96,971	13,63,378	1773,12,712

2) The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) on Cash Flow Statement.

CHARTERED ACCOUNTANTS FRN-109094 W

MUMP

As per our attached report of even date For R.S.SANGHAI & ASSOCIATES Chartered Accountants

R.S.SANGHAI

Partner Place : Mumbai

Dated: 22nd May, 2017

For and on behalf of the Board

Manish Narang

S & B HOLDINGS B.V. SEPARATE FINANCIAL STATEMENTS STATEMENT OF CHANGES IN EQUITY FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

				EURO
(a) Equity share capital	As at 31st March	, 2017	As at 31st Mar	ch, 2016
	No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the reporting period	355,90,552	355,90,552	355,90,552	355,90,552
Changes in equity share capital during the year	· ·		677	
Balance at the end of the reporting period	355,90,552	355,90,552	355,90,552	355,90,552
				Rs
a) Equity share capital	As at 31st March	, 2017	As at 31st Mar	ch, 2016
	No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the reporting period	355,90,552	28972,17,375	355,90,552	28972,17,375
Changes in equity share capital during the year		740	2	393
Balance at the end of the reporting period	355,90,552	28972.17.375	355.90.552	28972,17,375

Dominutare	Reserves and Surplus	Total other equity
Particulars	Retained Earnings	Total other equity
Balance at 1st April, 2015	91,40,439	91,40,439
Total Comprehensive		
Profit for the year ended 31st March, 2016	(66,63,279)	(66,63,279)
Other Comprehensive Income		
Balance at 31st March, 2016	24,77,160	24,77,160
Total Comprehensive		
Profit for the year ended 31st March, 2017	(61,69,984)	(61,69,984)
Other Comprehensive Income		155
Balance at the end of the reporting period	(36,92,824)	(36,92,824)

Particulars	Reserves and Surplus	Total other equity
Particulars	Retained Earnings	Total other equity
Balance at 1st April, 2015	1619,26,698	1619,26,698
Total Comprehensive		
Profit for the year ended 31st March, 2016	(3952,85,170)	(3952,85,170)
Other Comprehensive Income	TEL TEL	
Balance at 31st March, 2016	(2333,58,472)	(2333,58,472)
Total Comprehensive		
Profit for the year ended 31st March, 2017	(4722,15,526)	(4722,15,526)
Other Comprehensive Income		
Balance at the end of the reporting period	(7055,73,998)	(7055,73,998)



NOTE 1: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

1A General Information

These financial statements are prepared solely for the purposes of consolidation by the holding company, Alkem Laboratories Ltd.

1B SIGNIFICANT ACCOUNTING POLICIES:

1.1 Basis of preparation of Financial Statements:

The financial statements for the year ended 31st March, 2017 have been prepared in accordance with Ind AS issued and effective as at 31st March, 2016. The Company's opening Ind AS balance sheet was prepared as at 1st April, 2015, the Company's date of transition to Ind AS. In preparing the opening balance sheet, the Company has applied the mandatory exceptions and certain optional exemptions from full retrospective application of Ind AS in accordance with the guidance in Ind AS 101 'First Time Adoption of Indian Accounting Standards'.

These financial statements are the Company's first Ind AS financial statements and are covered by Ind AS 101, First-time adoption of Indian Accounting Standards. The transition to Ind AS has been carried out from the accounting principles generally accepted in India ("Indian GAAP") which is considered as the "Previous GAAP" for purposes of Ind AS 101. An explanation of how the transition to Ind AS has affected the Company's equity and its net profit is provided in Note 3.18.

The Company presents assets and liabilities in Balance Sheet based on current/non-current classification.

An asset is classified as current when it is:

- a) Expected to be realised or intended to sold or consumed in normal operating cycle,
- b) Held primarily for the purpose of trading,
- c) Expected to be realised within twelve months after the reporting period, or
- d) Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is classified as current when:

- a) it is expected to be settled in normal operating cycle.
- b) it is held primarily for the purpose of trading,
- c) it is due to be settled within twelve months after the reporting period.
- d) there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

1.2 Financial instruments

Financial instruments are recognised when the Company becomes a party to the contractual provisions of the instrument. Regular way purchases and sales of financial assets are recognised on trade-date, the date on which the Company commits to purchase or sell the asset,

Interest income

For all financial instruments measured at amortised cost and interest bearing financial assets, interest income is recognised using the effective interest rate (EIR), which is the rate that discounts the estimated future cash receipts through the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset.

When a loan and receivable is impaired, the Company reduces the carrying amount to its recoverable amount, being the estimated future cash flow discounted at the original EIR of the instrument, and continues unwinding the discount as interest income. Interest income on impaired financial asset is recognised using the original EIR.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value.

Reclassification of financial assets

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Company's senior management determines change in the business model as a result of external or internal changes which are significant to the group's operations. Such changes are evident to external parties. A change in the business model occurs when the group either begins or ceases to perform an activity that is significant to its operations. If the group reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The group does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.



The following table shows various reclassifications and how they are accounted for

Original classification	Revised classification	Accounting treatment
Amortised cost	FVTPL	Fair value is measured at reclassification date. Difference between previous amortized cost and fair value is recognised in statement of profit and loss.
FVTPL	Amortised Cost	Fair value at reclassification date becomes its new gross carrying amount. EIR is calculated based on the new gross carrying amount
Amortised cost	FVTOCI	Fair value is measured at reclassification date. Difference between previous amortised cost and fair value is recognised in OCI. No change in EIR due to reclassification.
FVOCI	Amortised cost	Fair value at reclassification date becomes its new amortised cost carrying amount. However, cumulative gain or loss in OCI is adjusted against fair value. Consequently, the asset is measured as if it had always been measured at amortised cost.
FVTPL	FVTOCI	Fair value at reclassification date becomes its new carrying amount. No other adjustment is required.
FVTOCI	FVTPL	Assets continue to be measured at fair value. Cumulative gain or loss previously recognized in OCI is reclassified to statement of profit and loss at the reclassification date.

(b) Financial Liabilities

The Company determines the classification of its financial liabilities at initial recognition.

Classification

The Company classifies all financial liabilities as subsequently measured at amortised cost, except for financial liabilities at fair value through profit or loss. Such liabilities, including derivatives that are liabilities, shall be subsequently measured at fair value.

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initial at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts and derivative financial instruments.

Financial liabilities at fair value through profit and loss

Financial liabilities at fair value through profit and loss include financial liabilities held for trading. The Company has not designated any financial liabilities upon initial recognition at fair value through profit and loss. Financial liabilities are classified as held for trading if they are acquired for the purpose of repurchasing in the near term. Derivatives are classified as held for trading unless they are designated as effective hedging instruments. At initial recognition, the Company measures financial liabilities at its fair value. Financial liabilities at fair value through profit and loss are carried in the Balance Sheet at fair value with changes recognised in the Statement of Profit and Loss.

Financial liabilities measured at amortised cost

Financial liabilities are initially recognised at fair value, net of transaction cost incurred and are subsequently measured at amortised cost, using the EIR method. Any difference between the proceeds net of transaction costs and the amount due on settlement or redemption of borrowings is recognised over the term of the borrowing.

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating interest charge over the relevant effective interest rate period. The effective interest rate is the rate that exactly discounts estimated future cash outflow (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the debt instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Derecognition of financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in the Statement of Profit and Loss.

(c) Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the company or the counter party.

1.3 Equity instruments

Equity instruments issued by the Company are classified according to the substance of the contractual arrangements entered into and the definitions of an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities and includes no obligation to deliver cash or other financial assets. Equity instruments issued by the Company are recorded at the proceeds received, net of direct issuance costs



NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

NOTE 1: SIGNIFICANT ACCOUNTING POLICIES: (Continued)

1.4 Revenue Recognition:

- a) Revenue is recognized to the extents that it is probable that the economic benefits will flow to the company and can be reliably measured.
- b) Interest Income is recognized on a time proportion basis taking into account the amount outstanding and applicable interest rate.
- c) Dividend income on investment is accounted for when the right to receive the payment is established.

1.5 Foreign currencies

i. Foreign currency transactions

Transactions in foreign currencies are translated into the respective functional currency of the Company at the exchange rates at the dates of the transactions. The functional and presentation currency of the Company is Indian Rupees.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Foreign currency differences are generally recognised in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not translated.

However, foreign currency differences arising from the translation of the following items are recognised in OCI:

- equity investments measured at fair value through other comprehensive income (except on impairment, in which case foreign currency differences that have been recognised in OCI are reclassified to profit or loss);
- · a financial liability designated as a hedge of the net investment in a foreign operation to the extent that the hedge is effective; and
- · qualifying cash flow hedges to the extent that the hedges are effective.

ii. Foreign Operations:

The assets and liabilities of foreign operations, and fair value adjustments arising on acquisition, are translated into Indian Rupees at the exchange rates at the reporting date. The income and expenses of foreign operations are translated into INR at the exchange rates at the dates of the transactions.

Foreign currency differences are recognised in OCI and accumulated in the translation reserve.

When a foreign operation is disposed of in its entirety or partially, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal.

1.6 Taxes on Income:

Income tax expense represents the sum of the current tax and deferred tax.

Current tax payable or recoverable is based on taxable profit for the year. Taxable profit differs from profit as reported in the Statement of Profit and Loss because some items of income or expense are taxable or deductible in different years or may never be taxable or deductible. The Company's liability for current tax is calculated using Indian tax rates and laws that have been enacted by the reporting date.

Current tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority.

The Company periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax is the tax expected to be payable or recoverable in the future arising from temporary differences between the carrying amounts of assets and liabilities in the Balance Sheet and the corresponding tax bases used in the computation of taxable profit. It is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset realised, based on tax rates that have been enacted or substantively enacted by the reporting date.

A deferred tax asset shall be recognised for the carry-forward of unused tax losses and unused tax credits to the extent that it is probable that future taxable profit will be available against which the unused tax losses and unused tax credits can be utilised.

Deferred income tax assets and liabilities are off-set against each other and the resultant net amount is presented in the Balance Sheet, if and only when the Company currently has a legally enforceable right to set-off the current income tax assets and liabilities

1.7 Borrowing Costs:

Borrowing costs are interest and other costs incurred by the Company in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of those tangible fixed assets which necessarily take a substantial period of time to get ready for their intended use are capitalised. Other borrowing costs are recognised as an expense in the Statement of Profit and Loss of the period in which they are incurred

1.8 Provision, Contingent Liabilities and Contingent Assets:

A provision is recognised if as a result of a past event, the Company has a present obligation (legal or constructive) that can be estimated reliably and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognised at the best estimate of the expenditure required to settle the present obligation at the balance sheet date. If the effect of time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability.

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount can not be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of outflow of resources is remote. Contingent assets are neither recognised nor disclosed in the financial statements. However, when the realisation of income is virtually certain, then the related asset is not a contingent asset and its recognition is appropriate.

1.9 Earnings per share ('EPS')

Basic EPS is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the period except where the results would be anti-dilutive.



S & B HOLDINGS B.V. NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

NOTE 2: Critical accounting judgements and key sources of estimation uncertainty

The Company prepares its financial statements in accordance with Ind AS as issued by the MCA, the application of which often requires judgements to be made by management when formulating the Company's financial position and results. The Directors are required to adopt those accounting policies most appropriate to the Company's circumstances for the purpose of presenting fairly the Company's financial position, financial performance and cash flows.

In determining and applying accounting policies, judgment is often required in respect of items where the choice of specific policy, accounting estimate or assumption to be followed could materially affect the reported results or net asset position of the Company should it later be determined that a different choice would be more appropriate.

Management considers the accounting estimates and assumptions discussed below to be its critical accounting estimates and, accordingly, provide an explanation of each below. The discussion below should also be read in conjunction with the Company's disclosure of significant accounting policies which are provided in note 3 to the consolidated financial statements, 'Significant accounting policies'.

a. Estimate of current and deferred tax

The Company's tax charge on ordinary activities is the sum of the total current and deferred tax charges. The calculation of the Company's total tax charge necessarily involves a degree of estimation and judgement in respect of certain items whose tax treatment cannot be finally determined until resolution has been reached with the relevant tax authority or, as appropriate, through a formal legal process. The final resolution of some of these items may give rise to material profits/losses and/or cash flows.

The complexity of the Company's structure makes the degree of estimation and judgement more challenging. The resolution of issues is not always within the control of the Company and it is often dependent on the efficiency of the legal processes in the relevant taxing jurisdictions in which the Company operates. Issues can, and often do, take many years to resolve. Payments in respect of tax liabilities for an accounting period result from payments on account and on the final resolution of open items. As a result there can be substantial differences between the tax charge in the Consolidated Statement of Profit and Loss and tax payments.

Recognition of deferred tax assets

The recognition of deferred tax assets is based upon whether it is more likely than not that sufficient and suitable taxable profits will be available in the future against which the reversal of temporary differences can be deducted. To determine the future taxable profits, reference is made to the latest available profit forecasts. Where the temporary differences are related to losses, relevant tax law is considered to determine the availability of the losses to offset against the future taxable profits.



S & B HOLDINGS B.V. NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

Particulars	As at 31st March, 2017 EURO	As at 31st March, 2017 Rs.	As at 31st March, 2016 EURO	As at 31st March, 2016 Rs.	As at 1st April, 2015 EURO	As at 1st April, 2015 Rs.
3.1: INVESTMENT IN SUBSIDIARY:						
nvestment in The Pharma Network LLC.	299,09,841	20534,64,903	299,09,841	20534,64,903	299,09,841	20534,64,904
TOTAL	299,09,841	20534.64.903	299,09,841	20534,64,903	299,09,841	20534,64,904
3.2 : NON CURRENT LOANS:	200,000,000					
oans and Advances to Subsidiary Companies	-		30,06,582	2249,60,549	31,49,337	2136,68,992
TOTAL		*	30,06,582	2249,60,549	31,49,337	2136,68,992
3.3 : OTHER NON-CURRENT ASSETS:						
Advance payment of Income Tax (Net of Provisions)	8,04,433	559,16,299	= =	(2)	- Al-	¥:
TOTAL	8,04,433	559,16,299	-	35	2.50	-
3.4 : INVESTMENTS:						
Berkshire Hathway TOTAL	16,367 16,367	11,37,646 11,37,646	11,256 11,256	8,42,233 8,42,233	11,256 11,256	8,91,486 8,91,486
3.5 : CASH AND CASH EQUIVALENTS: Balance with Banks:						
In Current Accounts	1,60,744	111,73,354	13,63,378	1020,11,618	11,35,091	770,11,037
TOTAL	1,60,744	111,73,354	13,63,378	1020,11,618	11,35,091	770,11,037
3.6 : OTHER CURRENT FINANCIAL ASSETS:						
Other receivable(Accrued interest)	:#//		6,32,223	473,04,650	4,87,026	330,42,609
TOTAL	241	120	6,32,223	473,04,650	4,87,026	330,42,609
3.7 : OTHER CURRENT ASSETS:	100					
Prepaid Expenses-	15,401	10,70,526	3	5.007		0.007
Other Receivable TOTAL	15,401	10,70,526	39	2,907 2,907	39 39	2,637 2,637
3.8 : SHARE CAPITAL:						
Authorised: 3,55,90,552 equity shares of Euro.1/- each fully paid up	355,90,552	28972,17,375	355,90,552	28972,17,375	355,90,552	28972,17,375
	355,90,552	28972,17,375	355,90,552	28972,17,375	355,90,552	28972,17,375
ISSUED, SUBSCRIBED & PAID-UP: 35,590,552 equity shares of Euro.1/- each fully paid up (Previous Year 35,590,552 equity shares of Euro.1/-each fully paid up)	355,90,552	28972,17,375	355,90,552	28972,17,375	355,90,552	28972,17,375
TOTAL	355,90,552	28972,17,375	355,90,552	28972,17,375	355,90,552	28972,17,375
OTHER EQUITY						
OTHER EQUITY Retained Earnings:						
At the commencement of the period/year	24,77,160	(2333,58,472)	91,40,439	1619,26,698	(9,99,722)	(4652,27,219
Add: Profit for the period/year	(61,69,984) (36,92,824)	(4722,15,526) (7055,73,998)	(66,63,279) 24,77,160	(3952,85,170) (2333,58,472)	101,40,161 91,40,439	6271,53,917 1619,26,698
Less: Appropriations: Transfer to General Reserve		(4)	(2)	2	-	*
At the end of the period/year	(36,92,824)	(7055,73,998)	24,77,160	(2333,58,472)		1619,26,698
TOTAL	(36,92,824)	(7055,73,998)	24,77,160	(2333,58,472)	91,40,439	1619,26,698
3.9 : OTHER CURRENT FINANCIAL LIABILITIES:						
Accrual for Expenses Others payables	17,000 42,281	11,81,673 29,38,934	76,723	57,40,598	210	14,23
Payable to TPN	85,80,548	5964,35,576	62,67,472	4689,49,146	3,09,003	209,64,52
TOTAL	86,39,828	6005,56,184	63,44,194	4746,89,744	3,09,213	209,78,75
3.10 : CURRENT TAX LIABILITIES (Net):						
For Income Tax (Net of Advance Tax)	12,64,155	878,71,641	14,51,042	1085,70,880	12,08,965	820,23,023
TOTAL	12,64,155	878,71,641	14,51,042	1085,70,880	12,08,965	820,23,0



S & B HOLDINGS B.V.
NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

Particulars	For the Year ended 31st March, 2017	For the Year ended 31st March, 2017	For the Year ended 31st March, 2016	For the Year ended 31st March, 2016
	EURO	Rs.	EURO	Rs.
3.11: OTHER INCOME:				
Interest on bank deposits	2,184	1,60,539	-	
Other interest	1,63,249	119,98,068	1,50,329	108,10,477
Provision no longer required, written back	*	5	210	15,084
Applicable net gain/loss on foreign currency transactions	2	-	38,969	866,87,474
Other Income	5,927	4,35,584	30,750	22,11,297
TOTAL	1,71,360	125,94,191	2,20,258	997,24,332
3.12 : FINANCE COST:				
Other borrowing cost	2,097	1,54,112	2,281	1,64,025
TOTAL	2,097	1,54,112	2,281	1,64,025
3,13 : OTHER EXPENSES:				
Legal and professional Fees	43,626	32,06,293	78,442	56,40,932
Applicable net gain/loss on foreign currency transactions and translation	1,15,888	272,65,859	740	*
Miscellaneous expenses	41	2,977	1 8 3	=
TOTAL	1,59,554	304,75,129	78,442	56,40,932



NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

3.14	Earnings per share (EPS)	 		
	Particulars		Year ended	Ye
	raiticulais		31st March, 2017	31st Ma

Particulars			Year ended 31st March, 2017	
Profit /(loss) after tax attributable to equity shareholders	Euro	А	(61,69,984)	(66,63,279)
Weighted average number of equity shares outstanding during the year	Nos.	В	355,90,552	355,90,552
Basic and diluted earnings per equity share	Euro	(A / B)	(0.17)	(0.19)

Euro

				Rs.
Particulars			Year ended 31 March, 2017	Year ended 31 March, 2016
Profit /(loss) after tax attributable to equity shareholders	Rs.	Α	(4722,15,526)	(3952,85,170)
Weighted average number of equity shares outstanding during the year	Nos.	В	355,90,552	355,90,552
Basic and diluted earnings per equity share	Rs.	(A / B)	(13.27)	(11.11)

3.15 Average exchange rate as on 31st March, 2017 considered for the purpose of translation as referred in note no. 1.5 ls Rs. 73.4956/1Euro (Rs.71.9121/1 Euro)

Closing exchange rate as on 31st March, 2017 considered for the purpose of translation as referred in note no. 1.5 is **Rs. 69.5102/1Euro** (Rs. 74.8227/1 Euro)



NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

3.16 Information on related party transactions as required by Indian Accounting Standard 24 (Ind AS 24) on related party disclosures for the financial year ended 31st March, 2017

List of related parties and their relationship

Company whose control exists Alkem Laboratories Limited

Wholly Owned Subsidlarles

ThePharmaNetwork, LLC (Wholly owned Subsidiary of S&B Holdings B.V.) Ascend Laboratories, LLC (Wholly owned by ThePharmanetwork, LLC)

Fellow Subsidiaries

Alkem Laboratories (NIG) Limited Alkem Laboratories (PTY) Limited Alkem Pharma GmbH Alkem Laboratories Corporation Pharmacor Pty Limited Ascend Laboratories SDN BHD. Ascend Laboratories SpA Enzene Biosciences Ltd. Alkem Laboratories Korea Inc Pharmacor Ltd. S & B Pharma Inc. The PharmaNetwork, LLP Ascend Laboratories (UK) Ltd.

Cachet Pharmaceuticals Pvt. Ltd Indchemie Health Specialities Pvt. Ltd

Key Managerial Personnel ("KMP")

Mr. Manish Narang

Nigeria South Africa Germany Philippines Australia Malaysia Chile India Korea Kenya

United States of America

Kazakhstan United Kingdom

India India

Management member board A

Details of Transactions with Related Parties

		Subsidiaries / Fellow	subsidiaries
Sr. No.	Particulars	EURO	Rs.
1	Loans repayment received (Pharmacor Pty Limited)	31,71,440	2330,87,005
2	Interest income on loans given(Pharmacor Pty Limited)	1,29,925 (1,50,329)	95,48,921 (108,10,477)
3	Tax paid by TPN on our behalf by The Pharma Network LLC.	68,12,116 (57,42,641)	5006,60,822 (4448,32,090)

Balance due from / to the related Partles

		Subsidiaries / Fellow subsidiaries		
Sr. No.	Particulars	EURO	Rs.	
1	Other payable to The Pharma Network LLC	85,80,547 (62,67,472)	5964,35,571 (4689,49,146)	
	Loans and advances given	(30,06,582)	(2249,60,549)	
	Interest receivable	(6,32,223)	(473,04,650)	

^{*} All the related party transactions were made on terms equivalent to those that prevail in an arm's length transactions.



^{*} Figures in the brackets are the corresponding figures of the previous year.

NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

3.17 Financial Instrument fair values and risk management

Accounting classification and fair values

	As at 31st March 2017							
		Carrying	amount (USD)		Carrying amount (Rs.)			
Particulars	FVTPL	FVTOCI	Amortised Cost	Total	FVTPL	FVTOCI	Amortised Cost	Total
Financial assets								444.70.054
Cash and Cash Equivalents		*	1,60,744	1,60,744		-	111,73,354	111,73,354
Non-current investments			299,09,841	299,09,841		20	20790,38,995	20790,38,995
Current investments	16,367			16,367	11,37,646			11,37,646
	16,367		300,70,585	300,86,952	11,37,646	•	20902,12,349	20913,49,995
Financial liabilities			86,39,828	86,39,828	9		6005,56,183	6005,56,183
Trade and other payables	-		86,39,828	86,39,828			6005,56,183	6005,56,183

	As at 31st March 2016							
Particulars	Carrying amount (USD)			Carrying amount (Rs.)				
	FVTPL	FVTOCI	Amortised Cost	Total	FVTPL	FVTOCI	Amortised Cost	Total
Financial assets								
Cash and Cash Equivalents	- 3	59	13,63,378	13,63,378	36		1020,11,618	1020,11,618
Non-current investments		2	299,09,841	299,09,841		~	22379,35,023	22379,35,023
Current investments	11.256			11,256	8,42,233	-	2	8,42,233
Long-term loans and advances	-	-	30,06,582	30,06,582			2249,60,583	2249,60,583
Trade and other receivables			6,32,223	6,32,223	39	=	473,04,650	473,04,650
	11,256		349,12,024	349,23,280	8,42,233	н	26122,11,873	26130,54,107
Financial liabilities								
Other Non-Current financial liabilities Other Current financial liabilities			63,44,194	63,44,194			4746,89,744	4746,89,744
			63,44,194	63,44,194			4746,89,744	4746,89,744

	As at 1 April 2015							
Particulars		Carrying	amount (USD)		Carrying amount (Rs.)			
	FVTPL	FVTOCI	Amortised Cost	Total	FVTPL	FVTOCI	Amortised Cost	Total
Financial assets								
Cash and Cash Equivalents	*		11,35,091	11,35,091			770,11,037	770,11,037
Non-current investments	¥	-	299,09,841	299,09,841	-	3	20292,54,066	20292,54,066
Current investments	11,256			11,256	7,63,698			7,63,698
Long-term loans and advances		20.	31,49,337	31,49,337	~	2	2136,68,992	2136,68,992
Trade and other receivables		90	4,87,026	4,87,026			330,42,609	330,42,609
	11,256	140	346,81,295	346,92,551	7,63,698		23529,76,704	23537,40,402
Financial liabilities			2.00.042	2.00.712			209.78.755	209,78,755
Other Current financial liabilities	-	(20)	3,09,213 3.09,213	3,09,213 3,09,213			209,78,755	209,78,755
		141	3,09,213	3,09,213	-		205,10,100	200,10,100

The Company has exposure to the following risks arising from financial instruments:

• Credit risk;

• Liquidity risk; and

- Market risk

i. Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The board of directors has established the Risk Management Committee, which is responsible for developing and monitoring the Company's risk management policies. The committee reports regularly to the board of directors on its activities

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.



NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

3.17 Financial instrument fair values and risk management

ii. Cradit riek

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investments in debt securities.

The carrying amount of following financial assets represents the maximum credit exposure:

Trade and other receivables

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk of the industry and country in which customers operate.

Loans to subsidiaries

The Company has no exposure of as on 31 March 2017 (AUD 5,379,028: 31 March 2016) for loans given to subsidiaries. Such loans are classified as financial asset measured at amortised cost.

The Company did not have any amounts that were past due but not impaired at 31 March 2017 or 31 March 2016. The Company has no collateral in respect of these loans.

Cash and cash equivalents

The Company held cash and cash equivalents of USD 830 ,AUD 114481, CHF 41418 at March 31, 2017 (March 31, 2016: USD 1172788, AUD 3454060, CHF 59053).



NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

3.17 Financial instrument fair values and risk management

iii. Market risk

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Company's income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivables and payables and long term debt. We are exposed to market risk primarily related to foreign exchange rate risk. Thus, our exposure to market risk is a function of investing and borrowing activities and revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs.

Currency risk

The Company is exposed to currency risk on account of its borrowings, other payables, receivables and loans and advances in foreign currency. The functional currency of the Company is Indian Rupee. The Company has exposure to USD and AUD. The Company has not hedged this foreign currency exposure.

Exposure to currency risk

The currency profile of financial assets and financial liabilities as at 31st March, 2017, 31st March, 2016 and April 1, 2015 are as below:

31st March, 2017		31st March, 2017
USD	AUD	CHF
830	1,14,481	41,418
830	1,14,481	41,418
92,12,923	/ *	-
92,12,923	(*)	
31st March, 2016	31st March, 2016	31st March, 2016
USD	AUD	CHF
11,72,788	3,45,460	59,053
	53,79,028	-
11,72,788	57,24,488	59,053.0
65,90,863		÷.
65,90,863		
	92,12,923 92,12,923 31st March, 2016 USD 11,72,788 11,72,788	830 1,14,481 92,12,923 - 92,12,923 - 31st March, 2016 USD 31st March, 2016 USD AUD 11,72,788 3,45,460 53,79,028 11,72,788 57,24,488

The following significant exchange rates have been applied during the year

The following significant exchange rates have been applied during	Average	e rate	Year-end spot rate		
INR	31st March, 2017	31st March, 2016	31st March, 2017	31st March, 2016	April 1, 2015
EURO	73.50	71,91	69.51	75.40	67.19
USD	67.03	65,42	64.75	66,26	62.50
AUD	50.39	48.09	49.62	50.98	47.52
CHF	66.73	66.69	64.91	68,54	64.83

Sensitivity analysis

A reasonably possible strengthening (weakening) of the Indian Rupee against various foreign currencies at 31st March, would have affected the measurement of financial instruments denominated in foreign currencies and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

	Profit or I	loss	Equity, net of tax		
Effect in INR	Strengthening	Weakening	Strengthening	Weakening	
31st March,, 2017					
10% movement					
USD	(596,45,352)	596,45,352	(596, 45, 352)	596,45,352	
AUD	5,68,033	(5,68,033)	5,68,033	(5,68,033)	
CHF	2,68,860	(2,68,860)	2,68,860	(2,68,860)	
	(588,08,459)	588,08,459	(588,08,459)	588,08,459	
	Profit or	loss	Equity, ne	t of tax	
Effect in INR	Strengthening	Weakening	Strengthening	Weakening	
31st March,, 2016					
10% movement					
10% movement USD	(358,97,453)	358,97,453	(358,97,453)	358,97,453	
	(358,97,453) 291,83,441	358,97,453 (291,83,441)	(358,97,453) 291,83,441	358,97,453 (291,83,441)	
USD					



NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

3.18 First-time adoption of Ind AS

I. First-time adoption of Ind AS

The financial statements for the year ended March 31, 2016 have been prepared in accordance with Ind AS as issued and effective as at March 31, 2016. The Company's opening Ind AS balance sheet was prepared as at 1 April 2015, the Company's date of transition to Ind AS. In preparing the opening balance sheet, the Company has applied the mandatory exceptions and certain optional exemptions from full retrospective application of Ind AS in accordance with the guidance in Ind AS 101 'First Time Adoption of Indian Accounting Standards'.

This note explains the principal adjustments made by the Company in restating its Indian GAAP financial statements to Ind AS, in the opening balance sheet as at April 1, 2015 and in the financial statements as at and for the year ended 31 March 2016.

II. Exemptions from retrospective application

Ind AS 101 allows first-time adopters certain exemptions from the retrospective application of certain requirements under Ind AS. The Company has applied the following exemptions:

a) Cumulative translation difference for foreign operations

The Company has elected to use exemption from recognising and accumulating cumulative translation differences of its foreign operations in a separate component of equity on the date of transition. Hence, the cumulative translation differences for all the foreign operations are deemed to be zero at the date of the transition to Ind AS.

The remaining voluntary exemptions as per Ind AS 101 - First time adoption either do not apply or are not relevant to the Company

III. Exceptions from full retrospective application:

The mandatory exceptions either do not apply or are not relevant to the Company.



NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

3.17 Financial instrument fair values and risk management

iv. Market risk

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Company's income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivables and payables and long term debt. We are exposed to market risk primarily related to foreign exchange rate risk. Thus, our exposure to market risk is a function of investing and borrowing activities and revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs.

Currency risk

The Company is exposed to currency risk on account of its borrowings, other payables, receivables and loans and advances in foreign currency. The functional currency of the Company is Indian Rupee. The Company has exposure to USD and AUD. The Company has not hedged this foreign currency exposure.

Exposure to currency risk

The currency profile of financial assets and financial liabilities as at 31st March, 2017, 31st March, 2016 and April 1, 2015 are as below:

	31st March, 2017	31st March, 2017	31st March, 2017
	USD	AUD	CHF
Financial assets		THE PROPERTY.	
Cash and Cash Equivalents	830	1,14,481	
- Inchient the state of the sta	830	1,14,481	41,418
Financial liabilities			
Trade and other payables	92,12,923		-
and the second	92,12,923		
	31st March, 2016	31st March, 2016	31st March, 2016
	USD	AUD	CHF
Financial assets			50.050
Cash and Cash Equivalents	11,72,788	3,45,460	59,053
Long terms loans and advances		53,79,028	
	11,72,788	57,24,488	59,053.0
Financial liabilities			
Trade and other payables	65,90,863		8

The following significant exchange rates have been applied during the year

The following significant exchange rates	Average	rate	Year-end spot rate			
INR	31st March, 2017	31st March, 2016	31st March, 2017	31st March, 2016	April 1, 2015	
EURO	73.50	71.91	69.51	75.40	67.19	
USD	67.03	65.42	64.75	66.26	62.50	
AUD	50.39	48,09	49.62	50.98	47.52	
CHF	66.73	66.69	64.91	68.54	64.83	

Sensitivity analysis

A reasonably possible strengthening (weakening) of the Indian Rupee against various foreign currencies at 31st March, would have affected the measurement of financial instruments denominated in foreign currencies and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

	Profit or	Profit or loss			
Effect in INR	Strengthening Weakening Strengthening Weakening (596,45,352) 596,45,352 (596,45,352) 5,68,033 (5,68,033) 5,68,033 2,68,860 (2,68,860) 2,68,860 (588,08,459) 588,08,459 -588,08,459 Profit or loss Equity, net of to Strengthening Strengthening Weakening Strengthening W (358,97,453) 358,97,453 (358,97,453) 291,83,441 (291,83,441) (291,83,441) 291,83,441 291,83,441	Weakening			
31st March,, 2017					
10% movement					
USD	(596,45,352)	596,45,352	(596,45,352)	596,45,352	
AUD	5,68,033	(5,68,033)	5,68,033	(5,68,033)	
CHF	2,68,860	(2,68,860)	2,68,860	(2,68,860)	
	(588,08,459)	588,08,459	-588,08,459	588,08,459	
	Profit or	loss	Equity, ne	t of tax	
Effect in INR	Strengthening	Weakening	Strengthening	Weakening	
31st March,, 2016					
10% movement			()	050 07 450	
USD	(358,97,453)	358,97,453		358,97,453	
AUD	291,83,441	(291,83,441)	Contract and a fine of the	(291,83,441)	
CHF	3,484	(3,484)	3,484	(3,484)	
0111	(67,10,527)	67,10,527	(67, 10, 527)	67,10,527	



S & B HOLDINGS B.V. NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

3.18 (IV) Reconciliations under Ind AS 101

N R	econciliation of Equity as at 1 April 2015		EURO		Rs,			
7.10	coordination of Equity as at 1 repril 2010	Previous GAAP	Adjustments	IND AS	Previous GAAP	Adjustments	IND AS	
Particulars		As at	As at	As at	As at	As at	As at	
		April 1, 2015	April 1, 2015	April 1, 2015	April 1, 2015	April 1, 2015	April 1, 2015	
	ASSETS							
	Non-Current Assets							
(a)	Investment in subsidiary	299,09,841	950	299,09,841	20534,64,904	-	20534,64,904	
(b)	Financial Assets						0400 00 000	
	(i) Loans	31,49,337	S#E	31,49,337	2136,68,992	7040 04 400	2136,68,993 7840,64,18	
(c)	Deferred tax assets (net)	15	115,56,579	115,56,579	:-	7840,64,186	7040,04,10	
	Current Assets							
. ,	Financial Assets			44.050	0.04.400		8,91,48	
	(i) Investments	11,256		11,256	8,91,486 770,11,037	360	770,11,03	
	(ii) Cash and Cash Equivalents	11,35,091	5:	11,35,091 4,87,026	330,42,609		330,42,60	
	(iii) Others	4,87,026	*		2,636	150	2,63	
(b)	E	39		39		E040.04.400		
	TOTAL ASSETS	346,92,590	115,56,579	462,49,169	23780,81,665	7840,64,186	31621,45,85	
	EQUITY AND LIABILITIES				1			
	Equity							
(a)	Equity Share Capital	355,90,552	-	355,90,552	28972,17,375	*	28972,17,37	
b)	Other Equity	(51,77,014)	143,17,453	91,40,439	(8359,98,222)	9979,24,920	1619,26,69	
	LIABILITIES							
	Non-current Liabilities							
a)	Deferred tax liabilities (net)	27,60,874	(27,60,874)	*	2138,60,733	(2138,60,733)	14	
	Current Liabilities							
(a)	Financial liabilities							
u)	(i) Other financial liabilities	3,09,213	2	3,09,213	209,78,755	-	209,78,75	
(b)	**	12,08,964	-	12.08,964	820,23,023		820,23,02	
(0)	TOTAL EQUITY AND LIABILITIES	346,92,589	115,56,579	462,49,168	23780,81,665	7840,64,186	31621,45,85	

(II) Notes to reconciliation between previous GAAP to Ind AS:

Under the Indian GAAP, the Company did not recognised the internally generated Goodwill acquired in the acquisition of the Pharmanetwork LLP, in the financial statements. However, the deferred tax liability on the said Goodwill was aggregated in the financial statement in accordance with the previous GAAP with no adjustment. However, under IND AS, deferred tax shall be recognized only on the temporary differences, resulting in the creation of net deferred tax asset of Euro 8,795,705 (Rs.997,924,920) on said goodwill with a corresponding gain recognised in retained earnings.



NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

3.18 (IV) Reconciliations under Ind AS 101

(iii) Reconciliation of Equity as at 31 March	2016	EURO		Rs.			
	Previous GAAP	Adjustments	IND AS	Previous GAAP	Adjustments	IND AS	
Particulars	As at	As a					
	31st March, 2016						
ASSETS							
Non-Current Assets							
(a) Investment in subsidiary	299,09,841	20	299,09,841	20534,64,904	2	20534,64,904	
(b) Loans	30,06,582	,ec	30,06,582	2249,60,549		2249,60,548	
(c) Deferred tax assets (net)	*	109,39,630	109,39,630	*	8185,32,666	8185,32,666	
Current Assets							
(a) Financial Assets							
Investments	11,256	160	11,256	8,42,233		8,42,233	
Cash and cash equivalents	13,63,378	3)	13,63,378	1020,11,618	*	1020,11,618	
Others	6,32,223		6,32,223	473,04,650		473,04,650	
(b) Other current assets	39	(4)	39	2,908		2,908	
TOTAL ASSETS	349,23,318	109,39,630	458,62,949	24285,86,861	8185,32,666	32471,19,526	
EQUITY AND LIABILITIES							
Equity							
(a) Equity Share Capital	355,90,552	141	355,90,552	28972,17,375		28972,17,375	
(b) Other Equity	(118,40,293)	143,17,453	24,77,160	(13046,28,950)	10712,70,478	(2333,58,472	
LIABILITIES							
Non-current Llabilities							
(a) Deferred tax liabilities (net)	33,77,823	(33,77,823)		2527,37,812	(2527,37,812)		
Current Llabilities			10				
(a) Other financial liabilities	63,44,194		63,44,194	4746,89,744	3.	4746,89,744	
(b) Current tax liabilities (net)	14,51,042	743	14,51,042	1085,70,880	2	1085,70,880	
TOTAL EQUITY AND LIABILITIES	349,23,318	109,39,630	458,62,948	24285,86,861	8185,32,666	32471,19,527	

(iv) Notes to reconcillation between previous GAAP to Ind AS:

Under the Indian GAAP, the Company did not recognised the internally generated Goodwill acquired in the acquisition of the Pharmanetwork LLP, in the financial statements. However, the deferred tax liability on the said Goodwill was aggregated in the financial statement in accordance with the previous GAAP with no adjustment. However, under IND AS, deferred tax shall be recognized only on the temporary differences, resulting in the creation of net deferred tax asset of Euro 8,795,705 (Rs.997,924,920) on said goodwill with a corresponding gain recognised in retained earnings.



NOTE 3: NOTES TO THE SEPARATE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2017

3.18 (IV) Reconciliations under Ind AS 101

(v) Reconciliation of profit or loss for the year ended 31 March 2016

		EURO					
	Particulars	Previous GAAP	Adjustments	IND AS	Previous GAAP	Adjustments	IND AS
	Particulars	2015-16	2015-16	2015-16	2015-16	2015-16	2015-16
T	Revenue from Operations	12	-	(#)	2.5	- 1	
ш	Other Income	2,20,258	(2)	2,20,258	263,78,773	733,45,559	997,24,332
Ш	Total Income (I+II)	2,20,258		2,20,258	263,78,773	733,45,559	997,24,332
IV	EXPENSES						
	Finance Cost	2,281	(*)	2,281	1,64,025		1,64,025
	Other expenses	78,442	(#C	78,442	56,40,932	- 8	56,40,932
	Total Expenses (IV)	80,723	-	80,723	58,04,957	-	58,04,957
٧	(Loss)/Profit before tax (III-IV)	1,39,535	1 4	1,39,535	205,73,816	733,45,559	939,19,375
VI	Tax expenses						
	Current tax	61,85,866	1981	61,85,866	4448,38,511		4448,38,511
	Deferred tax	6,16,948	*	6,16,948	443,66,033	=	443,66,033
VII	Profit/(Loss) for the year (V-VI)	(66,63,279)	I KAE	(66,63,279)	(4686,30,729)	733,45,559	(3952,85,170
VIII	Other Comprehensive Income				Î		
	(i) Items that will be reclassified to profit or loss	•	æ8	*	⇒ c	*))e:
	Total Other Comprehensive Income (VIII)	2				\$	
IX	Total Comprehensive Income for the period (VII+VIII) (Comprlsing profit/ (Loss) and Other Comprehensive Income for the period)	(66,63,279)		(66,63,279)	(4686,30,729)	733,45,559	(3952,85,170

3.19 Previous year figures have been regrouped wherever necessary to correspond with the figures of the current period.

CHARTERED

RN-109094 W

MUMBA

As per our attached report of even date

FOR R.S.SANGHAI & ASSOCIATES

Chartered Accountants

Partner

Place : Mumbai

Dated: 22nd May, 2017

For and on behalf of the Board

Manish Narang

11.000